Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge

International Immunopharmacology
Liu WeiLuo Ping

Abstract

Low-dose CpG ODN pretreatment is known to induce effective protective immunity against acute infectious diseases. In the present study, using primary murine peritoneal macrophages and the macrophage-like cell line, RAW264.7, we investigated whether low-dose CpG ODN pretreatment would induce hyporesponsiveness in response to a subsequent high-dose CpG ODN challenge and further investigated the molecular mechanisms underlying this event. Our results showed that pretreatment with a low dose of CpG ODN inhibits TNF-alpha production stimulated by later high-dose CpG ODN stimulation in a dose- and time-dependent manner. Interestingly, anti-mouse TLR9 blocking antibody added prior to CpG ODN pretreatment did not affect TNF-alpha release, but antibody added after CpG ODN pretreatment augmented the pretreatment effect of CpG ODN. This difference suggests that cell-surface TLR9 is indeed functional on activated cells. Flow cytometry revealed that low-dose CpG ODN pretreatment decreased cell-surface binding and internalization of a subsequent high-dose stimulation, suggesting that decreased internalization of succeeding CpG ODN is associated with reduced TNF-alpha release. Although both intracellular and cell-surface TLR9 expression are o...Continue Reading

References

Apr 6, 1995·Nature·A M KriegD M Klinman
Mar 27, 1997·Nature·T SparwasserH Wagner
Aug 25, 2000·The Journal of Biological Chemistry·Y OkazakiT Saito
Dec 29, 2000·Nature·H HemmiS Akira
Mar 21, 2001·Cellular Signalling·M Guha, N Mackman
Apr 18, 2001·Trends in Cell Biology·S JohnsonP Eggleton
Dec 19, 2001·Infection and Immunity·Nicole P JuffermansTom van der Poll
Jul 11, 2002·Microbes and Infection·Dennis M KlinmanMayda Gursel
Aug 2, 2002·Cell·Koichi KobayashiRichard A Flavell
Dec 20, 2002·Nature·Jonathan Cohen
Jan 24, 2003·Infection and Immunity·Susantha GomisAndrew Potter
Jan 13, 2004·Nature Immunology·Eicke LatzDouglas T Golenbock
Jan 31, 2004·Seminars in Immunology·Fumihiko TakeshitaDennis M Klinman
Jun 4, 2004·The Journal of Biological Chemistry·Margaret N KennedyDavid M Segal
Jul 2, 2004·Nature Reviews. Immunology·Richard J Ulevitch
Jul 24, 2004·Infection and Immunity·Surasakdi WongratanacheewinStitaya Sirisinha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.